| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 |
|---|---|---|---|---|---|---|---|---|---|
Operating activities: | |||||||||
Net income | |||||||||
-444 | -1,903 | -696 | -625 | -1,224 | 724 | 776 | 1,358 | 1,048 | 1,683 |
Adjustments to reconcile net income to net cash provided by (used in) operating activities: | |||||||||
Depreciation and amortization | |||||||||
583 | 810 | 900 | 984 | 1,003 | 961 | 952 | 954 | 1,109 | 1,244 |
Stock-based compensation | |||||||||
21 | 23 | 33 | 60 | 63 | 46 | 41 | 102 | 169 | 170 |
Non-cash life insurance policy reduction (accretion) | |||||||||
- | -20 | 120 | 117 | 100 | 91 | 68 | - | - | - |
Non-cash other revenue | |||||||||
345 | - | - | - | - | - | - | - | - | - |
Non-cash miscellaneous loss | |||||||||
24 | - | - | - | - | - | - | - | - | - |
(Gain) loss on sale of property, plant and equipment | |||||||||
434 | -0 | 8 | 0 | - | - | - | - | - | - |
Deferred income taxes | |||||||||
- | - | 508 | -3 | - | - | - | - | - | - |
Contribution of treasury shares to ESOP | |||||||||
- | - | - | - | - | - | 125 | 125 | 125 | 125 |
Non-cash gain on loan modification | |||||||||
- | - | - | - | - | - | - | 410 | 0 | - |
Deferred income taxes | |||||||||
- | - | - | - | 92 | -615 | -137 | 95 | -78 | -67 |
Foreign currency transaction (gain) loss | |||||||||
-11 | 32 | 20 | 147 | -109 | -136 | -126 | 21 | -29 | 69 |
(Increase) decrease in trade, accounts & notes receivable, and deposits from related parties | |||||||||
644 | 377 | -104 | 39 | - | - | - | - | - | - |
(Increase) decrease in accounts receivable and accounts due from employees and distributors | |||||||||
- | - | - | - | -156 | 117 | -84 | -115 | 40 | -72 |
(Increase) decrease in inventories | |||||||||
-843 | 26 | -15 | -537 | 138 | 76 | 3 | 468 | -899 | 471 |
(Increase) decrease in refundable income taxes | |||||||||
-0 | 3 | -70 | -425 | 264 | 257 | -11 | -83 | 34 | 38 |
(Increase) decrease in prepaid expenses and other current assets | |||||||||
-142 | 75 | -107 | -66 | -95 | -28 | 23 | 73 | 90 | -145 |
(Increase) decrease in other assets | |||||||||
- | - | 32 | 19 | -10 | 18 | 71 | 20 | -46 | 31 |
Increase (decrease) in income taxes payable | |||||||||
82 | 30 | 12 | 0 | - | -199 | 199 | 0 | - | - |
Increase (decrease) in accounts payable & accrued expenses, deferred revenue, and other noncurrent liabilities | |||||||||
-783 | 363 | -1,030 | 404 | - | - | - | - | - | - |
Increase (decrease) in accounts payable & accrued expenses and other noncurrent liabilities | |||||||||
- | - | - | - | -603 | -913 | 508 | 626 | -391 | -535 |
Net cash provided by (used in) operating activities | |||||||||
-942 | -1,169 | -156 | 1,525 | - | - | - | 2,468 | 2,792 | 2,227 |
Investing activities: | |||||||||
Proceeds from sale of property, plant, and equipment | |||||||||
- | 8 | 13 | 0 | 7 | 1 | 3 | 39 | 13 | 41 |
Net cash provided by operating activities | |||||||||
- | - | - | - | -799 | -391 | 2,522 | - | - | - |
Purchase of property, plant and equipment | |||||||||
98 | 181 | 499 | 173 | 250 | 909 | 382 | 524 | 414 | 618 |
Proceeds from redemption of life insurance policy | |||||||||
- | 3,066 | - | - | - | - | - | - | - | - |
Purchase of note and mortgage secured by underlying property | |||||||||
- | - | - | - | - | - | - | 2,000 | 0 | - |
Payments received on notes receivables - related parties | |||||||||
162 | 115 | 109 | 102 | 96 | 91 | 78 | 0 | - | - |
Repayment of revolving line of credit borrowings | |||||||||
- | - | - | - | 500 | 0 | - | - | - | - |
Proceeds from long-term borrowings | |||||||||
- | - | - | - | 3,249 | 0 | - | - | - | - |
Net cash provided by investing activities | |||||||||
63 | 3,009 | -377 | -70 | - | - | - | -2,785 | -679 | -844 |
Financing activities: | |||||||||
Acquisition of lunasin technology license | |||||||||
- | - | - | - | - | - | 1,150 | 0 | - | - |
Payment of life insurance premiums | |||||||||
- | - | - | - | - | 252 | 252 | 300 | 279 | 267 |
Net cash provided by (used in) investing activities | |||||||||
- | - | - | - | -146 | -1,069 | -1,702 | - | - | - |
Proceeds from line of credit borrowings | |||||||||
500 | - | 500 | 0 | - | 500 | 1,150 | - | - | - |
Proceeds from revolving line of credit borrowings | |||||||||
- | - | - | - | - | - | - | 0 | - | - |
Principal payments on long-term borrowings | |||||||||
- | 3,045 | 363 | 1,017 | 3,482 | 633 | 630 | 709 | 566 | 521 |
Common stock dividends paid | |||||||||
- | - | - | - | - | - | 378 | 375 | 497 | 495 |
Proceeds from warrants exercised | |||||||||
- | - | - | - | - | - | 13 | 0 | - | - |
Purchase of stock for treasury | |||||||||
- | - | - | 2 | 0 | - | 5 | 71 | 120 | 0 |
Other | |||||||||
- | - | - | - | - | - | - | - | - | 0 |
Net cash provided by financing activities | |||||||||
500 | -3,045 | 136 | -1,019 | - | - | - | -1,156 | -1,184 | -1,015 |
Net cash used in financing activities | |||||||||
- | - | - | - | -733 | -133 | 149 | - | - | - |
Effect of exchange rate changes on cash and cash equivalents | |||||||||
- | - | - | - | -48 | -73 | -113 | - | - | - |
Effect of exchange rate changes on cash and cash equivalents | |||||||||
19 | -76 | 63 | -90 | - | - | - | 100 | -84 | 203 |
Increase (decrease) in cash and cash equivalents | |||||||||
-359 | -1,282 | -334 | 344 | -1,727 | -1,667 | 855 | -1,373 | 843 | 570 |
Supplementary disclosure of cash flow information: | |||||||||
Interest | |||||||||
47 | 99 | 99 | 94 | - | - | - | - | - | - |
Income taxes paid | |||||||||
355 | 66 | -52 | -398 | - | - | - | - | - | - |
Cash paid during the year for: Interest | |||||||||
- | - | - | - | 87 | 82 | 74 | 99 | 139 | 206 |
Cash paid during the year for: Income taxes paid (received), net | |||||||||
- | - | - | - | -68 | 320 | - | - | - | - |
Cash paid during the year for: Income taxes | |||||||||
- | - | - | - | - | - | 579 | 597 | 789 | 1,304 |
Issuance of promissory notes | |||||||||
- | - | - | - | 424 | 0 | - | - | - | - |
Issuance of company common stock | |||||||||
- | - | - | - | 117 | 0 | - | - | - | - |
Obligation for acquisition of lunasin technology license | |||||||||
- | - | - | - | - | - | 850 | 0 | - | - |
Obligation for acquisition of lunasin technology license | |||||||||
- | - | - | - | - | - | - | 0 | - | - |